Dapagliflozin in the Prevention of Post-Coronary Angioplasty Acute Kidney Injury

Inclusion Criteria: 1. Age 18 years or more. 2. Scheduled/non-emergent Percutaneous coronary intervention (PCI). 3. Post-index procedure Staged PCI with at least 14 days from contrast exposure. 4. Patient can fully understand the study information and sign informed consent. Exclusion Criteria: 1. Cardiogenic shock /need for inotrope or mechanical pump support. 2. Acute kidney injury as defined by KDIGO criteria (\<4 weeks) prior to PCI. 3. End-Stage Renal Disease prior to PCI (On renal replacement therapy). 4. Diabetes Mellitus type 1. 5. Active diabetic ketoacidosis or uncontrolled hyperglycemia (blood glucose \>400 mg/dl). 6. ST-segment elevation Myocardial Infarction undergoing index PCI. 7. Active Genitourinary infection. 8. Diagnostic Left Heart Catheterization without PCI. 9. Patients undergoing zero contrast PCI. 10. Participation in a randomized controlled pharmaceutical or treatment-related cardiac or pulmonary clinical study within 1 month prior to randomization. 11. Coexistent hemodynamically significant valvulopathy (Symptomatic and/or severe). 12. Patients with Acute Heart Failure admission \< 30 days prior to PCI. 13. Intercurrent illness resulting in volume depletion and hypotension (MAP\<60 mmHg). 14. Patients with a kidney transplant. 15. Any contrast exposure within 14 days. 16. Patients with estimated glomerular filtration rate (eGFR) \< 25 cc/min (Recommended eGFR threshold by Food and Drug Administration labeling). 17. Patients with an active intrinsic inflammatory or autoimmune renal pathology. 18. Women of child bearing age (\<50 years old). 19. Prison Inmates